Literature DB >> 25309084

Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation.

Francesco Vasuri1, Deborah Malvi1, Francesca Rosini1, Pamela Baldin1, Michelangelo Fiorentino1, Alexandro Paccapelo1, Giorgio Ercolani1, Antonio Daniele Pinna1, Rita Golfieri1, Antonio Maria Morselli-Labate1, Walter Franco Grigioni1, Antonia D'Errico-Grigioni1.   

Abstract

AIM: To define the histopathological features predictive of post-transplant hepatocellular carcinoma (HCC) recurrence after transarterial chemoembolization, applicable for recipient risk stratification.
METHODS: We retrospectively reviewed the specimens of all suspicious nodules (total 275) from 101 consecutive liver transplant recipients which came to our Pathology Unit over a 6-year period. All nodules were sampled and analyzed, and follow-up data were collected. We finally considered 11 histological variables for each patient: total number of nodules, number of viable nodules, size of the major nodule, size of the major viable nodule, occurrence of microscopic vascular invasion, maximum Edmondson's grade, clear cell/sarcomatous changes, and the residual neoplastic volume. Survival data were computed by means of the Kaplan-Meier procedure and analyzed by means of the Cox proportional hazards model. The multivariate linear regression and a k-means cluster analysis were also used in order to compute the standardized histological score.
RESULTS: The total number of nodules, the residual neoplastic volume (the total volume of all evaluated nodules minus the necrotic portion) and the microvascular invasion entered the Cox multivariate hazard model with HCC recurrence as dependent variable. The histological score was therefore computed and a cluster analysis sorted recipients into 3 risk groups, with 3.3%, 18.5% and 53.8% respectively of tumor recurrence rates and 1.6%, 11.1% and 38.5% of tumor-related mortality respectively at the end of follow-up.
CONCLUSION: The histological score allows a reliable stratification of HCC recurrence risk, especially in those recipients found out to be beyond the Milan criteria after orthotopic liver transplantation (OLT).

Entities:  

Keywords:  Cancer recurrence; Chemoembolization; Hepatocellular carcinoma; Histopathology; Orthotopic liver transplantation; Transarterial chemoembolization

Mesh:

Year:  2014        PMID: 25309084      PMCID: PMC4188905          DOI: 10.3748/wjg.v20.i37.13538

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma.

Authors:  D M Harnois; J Steers; J C Andrews; J C Rubin; H C Pitot; L Burgart; R H Wiesner; G J Gores
Journal:  Liver Transpl Surg       Date:  1999-05

2.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

3.  Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI.

Authors:  Jordi Rimola; Alejandro Forner; Silvia Tremosini; Maria Reig; Ramón Vilana; Luis Bianchi; Carlos Rodríguez-Lope; Manel Solé; Carmen Ayuso; Jordi Bruix
Journal:  J Hepatol       Date:  2012-02-04       Impact factor: 25.083

4.  Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria.

Authors:  M Ravaioli; G L Grazi; F Piscaglia; F Trevisani; M Cescon; G Ercolani; M Vivarelli; R Golfieri; A D'Errico Grigioni; I Panzini; C Morelli; M Bernardi; L Bolondi; A D Pinna
Journal:  Am J Transplant       Date:  2008-12       Impact factor: 8.086

Review 5.  Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience.

Authors:  Vincenzo Mazzaferro; Sherrie Bhoori; Carlo Sposito; Marco Bongini; Martin Langer; Rosalba Miceli; Luigi Mariani
Journal:  Liver Transpl       Date:  2011-10       Impact factor: 5.799

6.  Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas.

Authors:  Rita Golfieri; Alberta Cappelli; Alessandro Cucchetti; Fabio Piscaglia; Maria Carpenzano; Eugenia Peri; Matteo Ravaioli; Antonia D'Errico-Grigioni; Antonio Daniele Pinna; Luigi Bolondi
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

7.  Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Bresson-Hadni; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Karim Boudjema; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Dhumeaux; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2005-07       Impact factor: 5.799

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

9.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.

Authors:  Iwao Ikai; Shigeki Arii; Masamichi Kojiro; Takafumi Ichida; Masatoshi Makuuchi; Yutaka Matsuyama; Yasuni Nakanuma; Kiwamu Okita; Masao Omata; Kenichi Takayasu; Yoshio Yamaoka
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  3 in total

1.  Exogenous sickle erythrocytes combined with vascular disruption trigger disseminated tumor vaso-occlusion and lung tumor regression.

Authors:  Chiao-Wang Sun; Li-Chen Wu; Mamta Wankhede; Dezhi Wang; Jutta Thoerner; Lawrence Woody; Brian S Sorg; Tim M Townes; David S Terman
Journal:  JCI Insight       Date:  2019-02-19

Review 2.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

3.  Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels.

Authors:  Wong Hoi She; Albert Chi Yan Chan; Tan To Cheung; Chung Mau Lo; Kenneth Siu Ho Chok
Journal:  World J Hepatol       Date:  2018-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.